ABT · NYSE
Medical Devices · United States
Snapshot 2026-11-11 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2027-01-28 (provider estimate; issuer confirmation unavailable here).
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Company websiteQ3 2026
Published 2026-10-21
Q3 2026 REPORT HIGHLIGHTS
Abbott reported 14.5% sales growth and 9.2% adjusted EPS growth. We separate acquisition effects, specified charges, cash demands and the planned Nutrition separation.
Reported sales rose 14.5%; the issuer’s comparable measure rose 7.0%. The calculation adds historical Exact Sciences revenue to the prior base and adjusts FX and an expiring structural-heart agreement.
Adjusted EPS rose 9.2% to $1.42 while GAAP EPS fell43.6% to $0.53. Pretax specified items of $1.689B include $841M intangible amortization and approximately $670M legal settlements.
The release does not provide September cash-flow or balance-sheet statements. June30 net debt was $27.005B; first-half FCF was $2.907B before dividends and repurchases.
The plan targets end2027, subject to conditions. Distributed shares, debt allocation, taxes and stranded costs determine shareholder value; no automatic separation premium is assumed.
The historical Q2 judgment remains intact. The updated integrated cash and debt analysis supports $90 central value rather than treating a falling share price or higher adjusted EPS as sufficient evidence to buy.
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | ABTAbbott LaboratoriesSnapshot 2026-11-11Financial period: 2026-09-30 |
|---|---|
| Market capMarket value, converted to USD | US$189.28B |
| Forward P/EProvider forward earnings estimate | 18.41x |
| EV / EBITDAEnterprise value / trailing EBITDA | 19.12x |
| Revenue growthLatest quarter vs prior-year quarter | 14.5% |
| Operating marginLatest reported quarter | 15.6% |
| Free cash flow yieldTrailing cash flow / market cap | 3.2% |
| Net debt / EBITDANet debt / trailing EBITDA | 2.37x |
| Debt / equityTotal debt / positive book equity | 0.61x |
| Trailing P/ETrailing twelve-month earnings | 40.78x |
| Price / bookPrice / positive book equity per share | 3.71x |
| EV / salesEnterprise value / trailing revenue | 4.54x |
| Earnings growthLatest quarter vs prior-year quarter | -43.6% |
| Gross marginTrailing twelve months | 57.2% |
| Net marginTrailing twelve months | 9.7% |
| Return on equityProvider trailing return; positive equity only | 9.1% |
| Free cash flow marginTrailing free cash flow / revenue | 12.6% |
| Dividend yieldIndicated annual dividend / price | 2.3% |
| Earnings payoutProvider trailing dividend payout | 92.5% |
| Current ratioCurrent assets / current liabilities | 1.46x |
| BetaProvider historical market sensitivity | 0.54 |
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-11-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
FREE RESEARCH PACKET · Q3 2026
Abbott reported 14.5% sales growth and 9.2% adjusted EPS growth. We separate acquisition effects, specified charges, cash demands and the planned Nutrition separation.
Research published October 21, 2026 · Download original report
Read Research PacketPresentation · 2026-10-21 · YouTube
Presentation · 2026-04-18 · YouTube
Presentation · 2026-04-13 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.
